32.87
-0.26 (-0.78%)
| Penutupan Terdahulu | 33.13 |
| Buka | 33.07 |
| Jumlah Dagangan | 118,355 |
| Purata Dagangan (3B) | 359,142 |
| Modal Pasaran | 1,660,934,912 |
| Harga / Jualan (P/S) | 4.38 |
| Harga / Buku (P/B) | 4.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | -6.48% |
| Margin Operasi (TTM) | -3.85% |
| EPS Cair (TTM) | -0.430 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 33.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 864.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 114.67% |
| Nisbah Semasa (MRQ) | 6.36 |
| Aliran Tunai Operasi (OCF TTM) | 31.08 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -21.36 M |
| Pulangan Atas Aset (ROA TTM) | -1.83% |
| Pulangan Atas Ekuiti (ROE TTM) | -5.86% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Immunocore Holdings plc | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -2.0 |
| Purata | -0.38 |
|
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 5.18% |
| % Dimiliki oleh Institusi | 97.28% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 55.00 (UBS, 67.33%) | Beli |
| Median | 45.50 (38.42%) | |
| Rendah | 36.00 (Morgan Stanley, 9.52%) | Pegang |
| Purata | 45.50 (38.42%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 34.38 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| UBS | 07 Jan 2026 | 55.00 (67.33%) | Beli | 33.76 |
| Morgan Stanley | 10 Nov 2025 | 36.00 (9.52%) | Pegang | 35.00 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 30 Jan 2026 | Pengumuman | Immunocore announces R&D leadership evolution |
| 09 Jan 2026 | Pengumuman | Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference |
| 10 Nov 2025 | Pengumuman | Immunocore to present at upcoming investor conferences |
| 07 Nov 2025 | Pengumuman | Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting |
| 06 Nov 2025 | Pengumuman | Immunocore reports third quarter financial results and provides a business update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |